ALX Oncology

ALX Oncology's CD47 Drug Shows Enhanced Response in Solid Tumors, Aiming for Phase 3 Trials

ALX Oncology’s CD47 Drug Shows Enhanced Response in Solid Tumors, Aiming for Phase 3 Trials

Anika Sharma

ALX Oncology is reevaluating the potential of its anti-CD47 drug in the context of solid tumors, buoyed by promising data. ...